The global market for Antibody Drugs reached $80.8 billion in 2016. The market should reach $114.6 billion by 2022 increasing from $84.5 billion in 2017, at a compound annual growth rate (CAGR) of 6.3% from 2017 through 2022.
Report Includes
-An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
-Analyses of global market trends, with data from 2014, 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
-Analysis and assessment of the therapeutic applications of mAbs in human medicine.
-A look at the antibody industry as a whole, as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
-Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industries in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.
Request a sample copy of Antibody Drugs Market Report @ https://www.bharatbook.com/request-sample/556868
Study Goals and Objectives
Monoclonal antibodies are a type of bioengineered protein drugs. These drugs are widely used in the treatment of a variety of chronic diseases such as cancer; autoimmune diseases such as multiple sclerosis; rheumatoid arthritis; cardiovascular diseases; and other diseases such as asthma, osteoporosis, etc. Research’s goal in conducting this study is to provide an overview of the current and future global market for antibody drug products.
This report explores the present and future strategies of the companies in the antibody drug product market, which includes murine mAbs, chimeric mAbs, human mAbs and humanized mAbs. The holdups and the needs of the market are discussed in this report. The classifications, comparisons and usage of these products are also portrayed in this report.
A detailed analysis of the antibody drug product industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period of 2017 through 2022. Applications for antibody drug products are also discussed. The report also covers significant patents and their allotments in each product category.
Reasons for Doing This Study
The antibody drug industry is one of the fast -growing industries in the pharmaceutical sector. A reason for this is that these drugs have fewer side effects than chemical drugs. Various biopharmaceutical companies are making their way into the antibody protein drug market. Manufacturing companies are focusing on the production of protein drugs. Antibody drug products have become important part of the biomedical industry. The pharmaceutical industry is undergoing a change from chemical drugs to protein drugs due to their high specificity, enhanced efficacy, affinity, solubility and low toxicity.
R&D spending, increasing competition and evolving technologies are providing a new direction to the market. This study looks at the systems affected by these trends.
Companies’ acquisition strategies and collaborative agreements are also covered in this report. This study also discusses the strength and weaknesses of each type of monoclonal antibody in light of the new technologies, growing competition and changing customer needs.
Scope of Report
This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.
Publisher Research analyzes and makes projections for each market and its applications, the regulatory environment, new products and technological advances. Also included in the report are relevant patent analysis and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd. and Merck & Co.
The report covers the major markets of the U.S. and Europe, as well as emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc.
Monoclonal antibodies are protein-based therapies/drugs that are finding use in the treatment of number of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.
The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human and humanized antibodies.
Excluded from this report are polyclonal antibodies; screening kits; and diagnostic uses of mAbs. Also excluded are research applications of mAbs and therapeutic antibodies for veterinary use.
Information Sources
Many companies were surveyed to obtain data for this study, including were manufacturers and end users of antibody drug products. Data was gathered from various industry sources. Publisher Research spoke with industry officials and consulted newsletters, company literature, product literature, technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were conducted. In addition, data were compiled from current financial, trade and government sources.
Methodology
Both primary and secondary research methodologies were used in preparing this study. Publisher Research conducted a comprehensive search of literature, which included technical newsletters, journals and other sources. Data were collected through interviews and correspondence with manufacturers and users of antibody drugs. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
Geographic Breakdown
In this report, the geographic regions considered for market analysis include, and only include:
The U.S.
Europe
All countries
Emerging markets
China
India
Japan
Korea
Taiwan
Africa
Australia
New Zealand
Canada
To read the complete report, click the link: https://www.bharatbook.com/biotechnology-market-research-reports-556868/antibody--drugs-technologies--global.html
About Bharat Book Bureau:
Bharat Book Bureau is the leading market research information provider for market research reports, company profiles, industry study, country reports, business reports, newsletters and online databases. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: poonam@bharatbook.com
Website: www.bharatbook.com
Follow us on : Twitter, Facebook, LinkedIn, Google Plus
Report Includes
-An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
-Analyses of global market trends, with data from 2014, 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
-Analysis and assessment of the therapeutic applications of mAbs in human medicine.
-A look at the antibody industry as a whole, as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
-Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industries in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.
Request a sample copy of Antibody Drugs Market Report @ https://www.bharatbook.com/request-sample/556868
Study Goals and Objectives
Monoclonal antibodies are a type of bioengineered protein drugs. These drugs are widely used in the treatment of a variety of chronic diseases such as cancer; autoimmune diseases such as multiple sclerosis; rheumatoid arthritis; cardiovascular diseases; and other diseases such as asthma, osteoporosis, etc. Research’s goal in conducting this study is to provide an overview of the current and future global market for antibody drug products.
This report explores the present and future strategies of the companies in the antibody drug product market, which includes murine mAbs, chimeric mAbs, human mAbs and humanized mAbs. The holdups and the needs of the market are discussed in this report. The classifications, comparisons and usage of these products are also portrayed in this report.
A detailed analysis of the antibody drug product industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period of 2017 through 2022. Applications for antibody drug products are also discussed. The report also covers significant patents and their allotments in each product category.
Reasons for Doing This Study
The antibody drug industry is one of the fast -growing industries in the pharmaceutical sector. A reason for this is that these drugs have fewer side effects than chemical drugs. Various biopharmaceutical companies are making their way into the antibody protein drug market. Manufacturing companies are focusing on the production of protein drugs. Antibody drug products have become important part of the biomedical industry. The pharmaceutical industry is undergoing a change from chemical drugs to protein drugs due to their high specificity, enhanced efficacy, affinity, solubility and low toxicity.
R&D spending, increasing competition and evolving technologies are providing a new direction to the market. This study looks at the systems affected by these trends.
Companies’ acquisition strategies and collaborative agreements are also covered in this report. This study also discusses the strength and weaknesses of each type of monoclonal antibody in light of the new technologies, growing competition and changing customer needs.
Scope of Report
This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.
Publisher Research analyzes and makes projections for each market and its applications, the regulatory environment, new products and technological advances. Also included in the report are relevant patent analysis and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd. and Merck & Co.
The report covers the major markets of the U.S. and Europe, as well as emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc.
Monoclonal antibodies are protein-based therapies/drugs that are finding use in the treatment of number of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.
The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human and humanized antibodies.
Excluded from this report are polyclonal antibodies; screening kits; and diagnostic uses of mAbs. Also excluded are research applications of mAbs and therapeutic antibodies for veterinary use.
Information Sources
Many companies were surveyed to obtain data for this study, including were manufacturers and end users of antibody drug products. Data was gathered from various industry sources. Publisher Research spoke with industry officials and consulted newsletters, company literature, product literature, technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were conducted. In addition, data were compiled from current financial, trade and government sources.
Methodology
Both primary and secondary research methodologies were used in preparing this study. Publisher Research conducted a comprehensive search of literature, which included technical newsletters, journals and other sources. Data were collected through interviews and correspondence with manufacturers and users of antibody drugs. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
Geographic Breakdown
In this report, the geographic regions considered for market analysis include, and only include:
The U.S.
Europe
All countries
Emerging markets
China
India
Japan
Korea
Taiwan
Africa
Australia
New Zealand
Canada
To read the complete report, click the link: https://www.bharatbook.com/biotechnology-market-research-reports-556868/antibody--drugs-technologies--global.html
About Bharat Book Bureau:
Bharat Book Bureau is the leading market research information provider for market research reports, company profiles, industry study, country reports, business reports, newsletters and online databases. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: poonam@bharatbook.com
Website: www.bharatbook.com
Follow us on : Twitter, Facebook, LinkedIn, Google Plus
Comments
Post a Comment